|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | α1-antichymotripsin regulates Alzheimer beta-amyloid peptide fibril formation显示文摘 | Eriksson S Janciauskiene S Lannfelt L | 1995 | Proc Natl Acad Sci USA1995，92，： | 1 |
| 2 | Disease progression correlates with decreasing CSF beta-amyloid in Alzheimer's patients with the swedish APP 670/671 mutation显示文摘 | Lannfelt L Basum H Wahlund LO | 1994 | Nenrobiol Aging1994，91，15： | 1 |
| 3 | Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase Ia, dou- ble-blind, randomised, placebo-controlled trial显示文摘 | LANNFELT L BLENNOW K ZETI'ERBERG H et ol | 2008 | The Lancet Neurology2008，7，9： | 1 |
| 4 | Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders显示文摘 | Lannfelt L Sokoloff P Martres MP | 1992 | Psychiatric Genet1992，，2： | 1 |
| 5 | Safety,efficacy,and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease:a phase Ⅱa,doubleblind,randomised,placebo-controlled trial显示文摘 | Lannfelt L Blennow K Zetterberg H | 2008 | Lancet Neurol2008，7，9： | 1 |
| 6 | Vascular risk factors and dementia: 40-year follow-up of a popula- tion-based cohort 显示文摘 | R6nnemaa E Zethelius B Lannfelt L | 2011 | Dement Geriatr Cogn Disord2011，31，6： | 1 |
| 7 | Apolipoprotein E epsilon4 genotype is independently associated with increased intima-media thickness in a recessive pattern显示文摘 | Wohlin M Sundstrom J Lannfelt L | 2007 | Lipids2007，42，5： | 1 |
| 8 | Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation显示文摘 | Eriksson S Janciauskiene S Lannfelt L | | 0，，： | 1 |
| 9 | α1-antichymotrypsin regulates Alzheimer β-amyloid peptide fibril formation显示文摘 | Eriksson S Janciauskiene S Lannfelt L | 1995 | Proc Nat Acad Sci USA1995，92，6： | 1 |
| 10 | Reduced expression of amyloid precursor protein, presenilin-1 and rab3a in cortical brain regions in Alzheimer's disease显示文摘 | Davidsson P Bogdanovic N Lannfelt L | 2001 | Dement Geriatr Cogn Disord2001，12，： | 1 |
| 11 | Lack cf association between an intronic polymorphism in the Presenilirrl gene and sporadic late-onset Alzheimei s disease in Polish patients显示文摘 | Kowalska A Wender M Lannfelt L | 1998 | Dement Geriatr Cogn Disorder1998，9，3： | 1 |
| 12 | Vascular risk factors and dementia:40-year follow-up of a population-based cohort显示文摘 | R(o)nnemaa E Zethelius B Lannfelt L | 2011 | Dement Geriatr Cogn Disord2011，31，6： | 1 |
| 13 | Disease progression correlations with decreasing CSF beta-amyloid in Alzheimer's patients with the Swedish APP 670/671 mutation显示文摘 | Basun H Wahlund LD | 1994 | Neurobiology1994，，： | 1 |
| 14 | Reduced expression of amyloid precursor protein,presenilin-1 and rab3a in cortical brain regions in Alzheimer's disease显示文摘 | Davidsson P Bogdanovic N Lannfelt L | 2001 | Dement Geriatr Cogn Disord2001，12，4： | 1 |
| 15 | Vascular risk factors and dementia: 40-year follow-up of a population-based cohort显示文摘 | Ronnemaa E Zethelius B Lannfelt L | 2011 | Dement Geriatr Cogn Disord2011，31，6： | 1 |
| 16 | Lack of association between schizophrenia and alleles in the dopamine D3 receptor gene 显示文摘 | JONSSON E LANNFELT L SOKOLOFF P | 1993 | Acta Psychiatr Scand1993，87，5： | 1 |
| 17 | Safety, efficacy, and bio- marker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer~ disease : a phase IIa, double-blind, randomised, placebo- controlled trial显示文摘 | Lannfelt L Blennow K Zetterberg H | 2008 | Lancet Neuro12008，7，9： | 1 |
| 18 | Abnormalities in Alzheimer's disease fibroblasts bearing the APP670/671 mutation 显示文摘 | Gibson GE Vestling M Zhang H Szolosi S Alkon D Lannfelt L Gandy S Cowburn RF | 1997 | Neurobiol Aging1997，18，6： | 1 |
| 19 | Safety, efficacy,and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease:a phase Ila,double-blind, randomised,placebo-controlled trial显示文摘 | Lannfelt L Blennow K Zetterberg H et aI | 2008 | Lancet Neurol2008，7，9： | 1 |
| 20 | Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, doubleblind, randomised, placebo-controlled trial 显示文摘 | Lannfelt L Blennow K Zetterberg H | 2008 | Lancet Neurol2008，7，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员